Neuro, That sounds similar to the analysis we were doing last year, in figuring (wrongly) whether a financing would be done before or after the Psychiatric decision. One big difference this time however, is that Stoll will know the clinical results way ahead of time, which is a big advantage.
The flip side for investors though, is that while Stoll will know the RD results early (perhaps in April), investors and the general public won't know the results until late June/early July at the earliest. Getting the pps up enough to justify a financing (say to $2-3), will probably require the official release of the RD results to the public (July), so that would put a financing in the late Summer.
There are other possible permutations on how this could unfold, so it'll be interesting. In addition to my blood pressure med, maybe I'll stock up on some Tagamet :o)
Market Data 
Markets 
AI
